Name | (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide |
---|---|
Synonyms |
(3'S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide
Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide,1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-,(3'S) Ubrogepant [USAN] MK-1602 Ubrogepant |
Description | Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1]. |
---|---|
Related Catalog | |
Target |
MK-1602[1] |
References |
Density | 1.45±0.1 g/cm3(Predicted) |
---|---|
Boiling Point | 729.4±60.0 °C(Predicted) |
Molecular Formula | C29H26F3N5O3 |
Molecular Weight | 549.54400 |
Exact Mass | 549.19900 |
PSA | 111.27000 |
LogP | 4.12840 |